ClinicaliQ Trial Snapshot
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) — Active Not Recruiting • Phase III • NCT06510816.
- Monthly eye injections of vonaprument tested to slow vision loss in dry age-related macular degeneration with geographic atrophy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA. Conditions: Geographic Atrophy Interventions: Vonaprument, Sham Administration Lead Sponsor: Annexon, Inc. Planned Enrollment: 659 participants